



Chronic Kidney Disease (CKD) CPM

- AMI Amini M, Salarifar M, Amirgaigloo A, Masoudkabar F, Esfahani F. N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial. *Trials*. 2009;10:45.
- BAK Bakris GL, Forman JP. Secondary factors and progression of chronic kidney disease. UpToDate. www.uptodate.com/contents/secondary-factors-and-progression-of-chronic-kidney-disease. Published Jan 2012. Updated May 2015. Accessed July 7, 2015.
- BAS Basturk T, Unsal A, Ulas T. Effect of cholecalciferol on parathyroid hormone and vitamin D levels in chronic kidney disease. *Minerva Urol Nefrol*. 2011;63(4):287–292.
- BEA Beathard GA, Urbanes A. Infection associated with tunneled hemodialysis catheters. *Semin Dial*. 2008;21(6):528–538.
- BMJ Moynihan R, Glasscock R, Doust J. Chronic kidney disease controversy: how expanding definitions are unnecessarily labelling many people as diseased. *BMJ*. 2013;347:f4298.
- CDC Centers for Disease Control and Prevention. National Chronic Kidney Disease Fact Sheet 2010. www.cdc.gov/diabetes/pubs/factsheets/kidney.htm. Accessed May 15, 2013.
- CHA Chapman AB, Rahbari-Oskoui FF, et al. UpToDate. Course and treatment of autosomal dominant polycystic kidney disease. www.uptodate.com/contents/course-and-treatment-of-autosomal-dominant-polycystic-kidney-disease. Published Jan 2012. Updated Aug 20103. Accessed September 26, 2013.
- DEB de Brito-Ashurst I, Varaganam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. *J Am Soc Nephrol*. 2009;20(9):2075–2084.
- EVA Evans KJ, Greenberg A. Hyperkalemia: a review. *J Intensive Care Med*. 2005;20(5):272–290.
- GOA Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. *N Engl J Med*. 2004;351(13):1296–1305.
- GRUY Gruy-Kapral C, Emmett M, Santa Ana CA, Porter JL, Fordtan JS, Fine KD. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease. *J Am Soc Nephrol*. 1998;9(10):1924–1930.
- HOL Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. *Am Fam Physician*. 2006;73(2):283–290.
- INK1 Inker LA, Perrone RD. Assessment of kidney function: Serum creatinine; BUN; and GFR. UpToDate. www.uptodate.com/contents/assessment-of-kidney-function-serum-creatinine-bun-and-gfr. Published Jan 2012. Updated August 2014. Accessed July 7, 2015.
- INK2 Inker LA, Okparavero A. Cystatin C as a marker of glomerular filtration rate: prospects and limitations. *Curr Opin Nephrol Hypertens*. 2011;20(6):631–639.
- ISR Israel GM, Bosniak MA. An update of the Bosniak renal cyst classification system. *Urology*. 2005;66(3):484–488.
- KAH Kahn T, Kaji DM, Nicolis G, Karkoff LR, Stein RM. Factors related to potassium transport in stable chronic renal disease in man. *Clin Sci Mol Med*. 1978;54(6):661–666.
- KDIGO Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney inter. Suppl*. 2013;3:1–150.
- KUR Kurella Tamura M, Covinsky KE, Chertow GM, Yaffe K, Landefeld CS, McCulloch CE. Functional status of elderly adults before and after initiation of dialysis. *N Engl J Med*. 2009;361(16):1539–1547.
- LEV1 Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009;150(9):604–612.
- LEV2 Levey AS, Tangri N, Stevens LA. Classification of chronic kidney disease: a step forward. *Ann Intern Med*. 2011;154(1):65–67.
- LUB Lubowsky ND, Siegel R, Pittas AG. Management of glycemia in patients with diabetes mellitus and CKD. *Am J Kidney Dis*. 2007;50(5):865–879.
- MAH Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. *Kidney Int*. 2010;78(3):303–309.
- MCD McDonald MM, Swagerty D, Wetzel L. Assessment of microscopic hematuria in adults. *Am Fam Physician*. 2006;73(10):1748–1754.
- MEL Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. *Arch Intern Med*. 2008;168(15):1629–1637.
- MIT Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced nephropathy after contrast-enhanced computed tomography in the outpatient setting. *Clin J Am Soc Nephrol*. 2010;5(1):4–9.
- MOO Moore ML, Bailey RR. Hyperkalaemia in patients in hospital. *N Z Med J*. 1989;102(878):557–558.
- MOU1 Mount DB. Treatment and prevention of hyperkalemia in adults. UpToDate. www.uptodate.com/contents/treatment-and-prevention-of-hyperkalemia. Published Jan 2012. Updated June 2015. Accessed July 7, 2015.
- MOU2 Mount DB. Causes and evaluation of hyperkalemia in adults. UpToDate. www.uptodate.com/contents/causes-of-hyperkalemia. Published Jan 2012. Updated October 2014. Accessed July 7, 2015.
- NKF1 National Kidney Foundation. KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. www.kidney.org/professionals/KDOQI/guidelines_bp/index.htm. Accessed August 2, 2013.
- NKF2 National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm. Accessed August 2, 2013.

- NKF3 National Kidney Foundation. KDOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. www.kidney.org/Professionals/Kdoqi/guidelines_bone/index.htm. Accessed August 2, 2013.
- NKF4 National Kidney Foundation. KDOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. www.kidney.org/professionals/KDOQI/guidelines_lipids/toc.htm. Accessed August 2, 2013.
- NRC National Research Council. *Health Risks From Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2*. Washington, DC: National Academies Press; 2006.
- NOG Nogueira J, Weir M. The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs. *Clin J Am Soc Nephrol*. 2007;2(4):766–785.
- PAP Papademetriou, V., Lovato, L., Doumas, M., Nysten, F., Mottl, A., Cohen, R.M., et al. Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. *Kidney International*. 2015;87:649–659.
- PER1 Perazella MA. Drug induced hyperkalemia: old culprits and new offenders. *Am J Med*. 2000;109(4):307–314.
- PER2 Perazella MA. Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link? *Clin J Am Soc Nephrol*. 2007;2(2):200–202.
- ROS2 Rose B, Post T. *Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed*. New York, NY: McGraw-Hill; 2001
- RUC Rucker D, Tonelli M, Coles MG, Yoo S, Young K, McMahon AW. Vitamin D insufficiency and treatment with oral vitamin D3 in northern-dwelling patients with chronic kidney disease. *J Nephrol*. 2009;22(1):75-82.
- RUD Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical consequences? *Clin J Am Soc Nephrol*. 2008;3(1):263–272.
- RYA Ryan TP, Sloand JA, Winters PC, Corsetti JP, Fisher SG. Chronic kidney disease prevalence and rate of diagnosis. *Am J Med*. 2007;120(11):981–986.
- SCH Schrier R, McFann K, Johnson A, et al. Cardiac and renal effects of standard versus rigorous blood pressure control in autosomal-dominant polycystic kidney disease: results of a seven-year prospective randomized study. *J Am Soc Nephrol*. 2002;13(7):1733–1739.
- SIN Sinnakirouchenan R, Holley JL. Peritoneal dialysis versus hemodialysis: risks, benefits, and access issues. *Adv Chronic Kidney Dis*. 2011;18(6):428–432.
- SKI Skipper A, ed. Nutrition Care Manual. Academy of Nutrition and Dietetics. October, 2014 release. nutritioncaremanual.org/category.cfm?ncm_category_id=11. Accessed July 7, 2015.
- TEX Textor S. UpToDate. Establishing the diagnosis of renovascular hypertension. www.uptodate.com/contents/screening-for-renovascular-hypertension. Published Jan 2012. Updated Sept 2014. Accessed July 7, 2015.
- TON Tonelli M, Muntner P, Lloyd A, et al; Alberta Kidney Disease Network. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study. *Ann Intern Med*. 2011;154(1):12–21.
- TOY Toyama K, Sugiyama S, Oka H, Sumida H, Ogawa H. Exercise therapy correlates with improving renal function through modifying lipid metabolism in patients with cardiovascular disease and chronic kidney disease. *J Cardiol*. 2010;56(2):142–146.
- TRA Trakarnvanich T, Chalapipat O, Disthabanchong S, et al. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency. *J Med Assoc Thai*. 2010;93(8): 885–891.
- USR1 U.S. Renal Data System. *USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2012.
- USR2 U.S. Renal Data System. *USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2010.
- USR3 U.S. Renal Data System. *USRDS 2008 Annual Data Report: Atlas of End-Stage Renal Disease in the United States*. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2008.
- VAN van der Velde M, Matsushita K, Coresh J; et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. *Kidney Int*. 2011;79(12):1341–1352.
- VAWG Vascular Access 2006 Work Group. Clinical practice guidelines for vascular access. *Am J Kidney Dis*. 2006;48(Suppl 1):S176–S247.
- WEI Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. *J Am Soc Nephrol*. 2004;15(5):1307–1315.
- YUS Yusuf S, Teo KK, Pogue J, et al; ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. *N Engl J Med*. 2008;358(15):1547–1559.